Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research data.

Wright CF, Fitzgerald TW, Jones WD, Clayton S, McRae JF, van Kogelenberg M, King DA, Ambridge K, Barrett DM, Bayzetinova T, Bevan AP, Bragin E, Chatzimichali EA, Gribble S, Jones P, Krishnappa N, Mason LE, Miller R, Morley KI, Parthiban V, Prigmore E, Rajan D, Sifrim A, Swaminathan GJ, Tivey AR, Middleton A, Parker M, Carter NP, Barrett JC, Hurles ME, FitzPatrick DR, Firth HV, DDD study. · 2015

Read Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research data. by Wright CF, Fitzgerald TW, Jones WD, Clayton S, McRae JF, van Kogelenberg M, King DA, Ambridge K, Barrett DM, Bayzetinova T, Bevan AP, Bragin E, Chatzimichali EA, Gribble S, Jones P, Krishnappa N, Mason LE, Miller R, Morley KI, Parthiban V, Prigmore E, Rajan D, Sifrim A, Swaminathan GJ, Tivey AR, Middleton A, Parker M, Carter NP, Barrett JC, Hurles ME, FitzPatrick DR, Firth HV, DDD study. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4392068.txt.

Introduction

Caroline Wright and a large Deciphering Developmental Disorders team reported scalable genetic diagnosis for children, in The Lancet in 2015. Genome reading was entering clinics for rare diseases, but labs needed robust pipelines to find causal variants and decide what to return to families. The British study recruited children with undiagnosed developmental disorders through all 24 regional genetics services, testing each child and their parents with microarrays and exome sequencing.

Each child carried about 80,000 variants, of which roughly 400 were rare and predicted to alter proteins. Focusing on new or inherited variants in known disorder genes gave a diagnosis for 27 percent of 1,133 children who had already been investigated without answers. Results went back to families through their local genetics teams. The yield shows genome-wide testing earns its place in routine rare-disease care.

Catalog record

CREATORWright CF, Fitzgerald TW, Jones WD, Clayton S, McRae JF, van Kogelenberg M, King DA, Ambridge K, Barrett DM, Bayzetinova T, Bevan AP, Bragin E, Chatzimichali EA, Gribble S, Jones P, Krishnappa N, Mason LE, Miller R, Morley KI, Parthiban V, Prigmore E, Rajan D, Sifrim A, Swaminathan GJ, Tivey AR, Middleton A, Parker M, Carter NP, Barrett JC, Hurles ME, FitzPatrick DR, Firth HV, DDD study.
YEAR2015
COLLECTIONPAPERS
FORMATTXT
FILE SIZE43 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4392068

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research data By Caroline F Wright, Tomas W Fitzgerald, Wendy D Jones, Stephen Clayton, Jeremy F McRae, Margriet van Kogelenberg, Daniel A King, Kirsty Ambridge, Daniel M Barrett, Tanya Bayzetinova, A Paul Bevan, Eugene Bragin Published in: Lancet (London, England) DOI: 10.1016/S0140-6736(14)61705-0 ABSTRACT Summary Background Human genome sequencing has transformed our understanding of genomic variation and its relevance to health and disease, and is now starting to enter clinical practice for the diagnosis of rare diseases. The question of whether and how some categories of genomic findings should be shared with individual research participants is currently a topic of international debate, and development of robust analytical workflows to identify and communicate clinically relevant variants is paramount. Methods The Deciphering Developmental Disorders (DDD) study has developed a UK-wide patient recruitment network involving over 180 clinicians across all 24 regional genetics services, and has performed genome-wide microarray and whole exome sequencing on children with undiagnosed developmental disorders and their parents. After data analysis, pertinent genomic variants were returned to individual research participants via their local clinical genetics team. Findings Around 80 000 genomic variants were identified from exome sequencing and microarray analysis in each individual, of which on average 400 were rare and predicted to be protein altering. By focusing only on de novo and segregating variants in known developmental disorder genes, we achieved a diagnostic yield of 27% among 1133 previously investigated yet undiagnosed children with developmental disorders, whilst minimising incidental findings. In families with developmentally normal parents, whole exome sequencing of the child and both parents resulted in a 10-fold reduction in the number of potential causal variants that needed clinical evaluation compared to sequencing only the child. Most diagnostic variants identified in known genes were novel and not present in current databases of known disease variation. Interpretation Implementation of a robust translational genomics workflow is achievable within a large-scale rare disease research study to allow feedback of potentially diagnostic findings to clinicians and research participants. Systematic recording of relevant clinical data, curation of a gene–phenotype knowledge base, and development of clinical decision support software are needed in addition to automated exclusion of almost all variants, which is crucial for scalable prioritisation and review of possible diagnostic variants. However, the resource requirements of development and maintenance of a clinical reporting system within a research setting are substantial. Funding Health Innovation Challenge Fund, a parallel funding partnership between the Wellcome Trust and the UK Department of Health. INTRODUCTION The increasing use of whole exome and whole genome sequencing in both research1, 2 and clinical practice3, 4, 5 raises questions about how to maximise the diagnostic usefulness of genomic data and how to share results with research participants and patients. Furthermore, it is increasingly deemed ethically desirable to return clinically useful results to research participants.6 However, return of individual genomic results poses major logistical challenges. A robust workflow must be developed to track individual samples and datasets, generate high-quality genomic data, filter out a very large number of probably benign variants, prioritise plausibly pathogenic variants, and link these findings to individual clinical data for interpretation and appropriate clinical follow-up. Health-related findings from a human genome could potentially include thousands of variants pertaining to hundreds of different conditions,7 almost none of which provide clinically useful information for a specific individual.8 A first step toward addressing these challenges is to separate potential genomic findings into those that are pertinent to a particular disease investigation and those that are non-pertinent (or incidental) to that disease. Although many commentators have debated the merits of returning different classes of findings from large research studies and biobanks,6, 9, 10 none has yet provided a scalable implementation from patient identification through to a confirmed diagnosis within a research context. Here we describe the development and implementation of a translational genomics workflow in a large-scale rare disease research study to communicate pertinent findings to individual research participants, whilst minimising incidental findings. The Deciphering Developmental Disorders (DDD) study11 is a UK-wide collaborative project that seeks to facilitate the translation of genomic sequencing technologies into the National Health Service (NHS), by collecting a set of high-resolution genomic and phenotypic data for children with severe undiagnosed developmental disorders and their parents. Although whole genome microarray analysis has already proven invaluable for identification of large pathogenic copy number variants (mostly deletions and duplications) in children with developmental disorders,12 most children remain undiagnosed. In many cases, the condition is caused by a de novo mutation that occurs spontaneously in the affected child somewhere in the genome,13, 14, 15 and if there is no family history of the condition the genetic basis of the diagnosis can be easily overlooked. The recruitment criteria for the study are focused on congenital or early onset severe phenotypes, and were specifically designed to maximise the chance of finding a highly penetrant monogenic cause for the child's condition. The study was established with the dual aim of assisting the translation of new high-throughput genomic technologies into clinical practice, and elucidating the underlying genetic architecture of developmental disorders. Cambridge South Research Ethics Committee (REC) approved the feedback of potentially causal variants from DDD to the patients' regional genetics centre, whose responsibility it is to assess and validate the findings before communicating them to the families with appropriate counselling regarding recurrence risk, likely prognosis, and potential clinical management. The judgment not to feed back incidental findings was REC-approved, and the protocol and patient information sheets clearly state that “incidental findings will not be reported back in the DDD study”. Nonetheless, we developed a parallel research study to investigate attitudes towards feeding back a broader range of genomic results to research participants.16, 17 We outline a process to identify and report likely causal variants (pertinent findings) in individual patients, and summarise the results to date. There are many different classes of disease-causing genetic variation, of which some are observed infrequently (eg, uniparental disomy, in which both copies of a single chromosome are inherited from one parent, which occurs in fewer than one in 1000 individuals18), whereas others are observed in huge numbers (eg, single DNA base changes, of which every individual has millions in their genome). Different genetic changes need different analysis methods; in particular, more numerous forms of genetic variation need a scalable automated approach. We describe the workflow we have developed to achieve a scalable genome-wide diagnostic analysis, focusing particularly on the automated part of a larger workflow, and we show the clinical usefulness of this workflow using data for 1133 probands with severe undiagnosed developmental disorders as an example. METHODS Clinical data collection We developed a workflow to facilitate patient recruitment, sample tracking, data generation, data analysis, variant filtering, manual curation, and feedback of results (figure 1; appendix 1). Clinically ascertained undiagnosed patients meeting the recruitment criteria (severe undiagnosed neurodevelopmental disorder and/or congenital anomalies, abnormal growth parameters, dysmorphic features, and unusual behavioural phenotypes) were recruited to the DDD study by their UK NHS or Irish Regional Genetics Service, who also recorded clinical information and phenotypes using the Human Phenotype Ontology (HPO)19 via a secure web portal within the DECIPHER database.20 A team of research coordinators (typically research

Read the complete text